Equity · Healthcare
CRSP
NASDAQCRISPR Therapeutics (CRSP)
The line runs 50 USD on 3 August through 51.40 USD on 30 October, on a scale from 45 to 65. Days the market did not trade hold the previous close, flat.
- Market cap
- 5.0B USD
- Revenue, year to Dec 2025
- 3.5M USD
- EPS, diluted, year to Dec 2025
- −6.47 USD
- 52-week range
- 44.32 USD – 68 USD
- Avg volume
- 69.8K
- Mentions, 30 days
- 23
- Net sentiment
- +0.08
as of Oct 30, 2026
Have CRISPR Therapeutics (CRSP) insiders bought or sold shares recently?
In the 90 days to 2 Nov 2026, CRISPR Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Oct 2025, show no open-market purchase.
Form 4, 90 days to 2 Nov 2026, newest reported trade 19 Oct 2026
Buys 0Sells 7Net sold $4.88MOther filings 8
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 19 Oct 2026 | Kulkarni SamarthChief Executive Officer | Sell | 47,837 | 2.4M USD |
| 14 Oct 2026 | George SimeonDirector | Sell | 14,514 | 720K USD |
| 14 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Sell | 1,040 | 51K USD |
| 14 Oct 2026 | Kulkarni SamarthChief Executive Officer | Sell | 4,098 | 202K USD |
| 06 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Sell | 1,990 | 119K USD |
| 22 Sep 2026 | KASINGER JAMES R.General Counsel and Secretary | Sell | 10,400 | 626K USD |
| 17 Sep 2026 | Behbahani AliDirector | Sell | 13,679 | 781K USD |
| Sold | 7 open-market sales | 93,558 | $4.88M |
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Oct 2026 | Kulkarni SamarthChief Executive Officer | Option exercise | 100,000 | |
| 14 Oct 2026 | George SimeonDirector | Option exercise | 30,000 | 420K USD |
| 13 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Option exercise | 2,113 | |
| 13 Oct 2026 | Kulkarni SamarthChief Executive Officer | Option exercise | 8,333 | |
| 06 Oct 2026 | KASINGER JAMES R.General Counsel and Secretary | Option exercise | 1,990 | 27K USD |
| 22 Sep 2026 | KASINGER JAMES R.General Counsel and Secretary | Option exercise | 10,400 | 142K USD |
| 17 Sep 2026 | Behbahani AliDirector | Option exercise | 30,000 | 420K USD |
| 07 Aug 2026 | Prasad RajuChief Financial Officer | Gift | 750 |
Which funds hold CRISPR Therapeutics (CRSP)?
9 of the 45 institutional funds we track reported a CRISPR Therapeutics position for the quarter ended 30 Jun 2026 — a combined 731.6M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| ARK Investment Management | Held (±25%) | 9,460,939 | 516.0M USD | −16.4% |
| Two Sigma Investments | Added | 1,988,621 | 108.5M USD | +34.1% |
| D. E. Shaw & Co. | New position | 893,812 | 48.7M USD | |
| Citadel Advisors | Held (±25%) | 465,796 | 25.4M USD | −9.8% |
| Millennium Management | Held (±25%) | 382,032 | 20.8M USD | +1.3% |
| Fisher Asset Management | New position | 77,960 | 4.3M USD | |
| Man Group | Held (±25%) | 73,194 | 4.0M USD | −18.7% |
| Tudor Investment Corp | Held (±25%) | 42,512 | 2.3M USD | −2.1% |
| AQR Capital Management | Added | 28,597 | 1.6M USD | +28.4% |
Have members of Congress traded CRISPR Therapeutics (CRSP)?
The most recent congressional trade disclosed in CRISPR Therapeutics is a purchase by Thomas R. Suozzi (house, NY), dated 03 Jun 2021.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 03 Jun 2021 | Thomas R. Suozzihouse · Democrat–NY | Purchase | 50K USD–100K USD | 112 days |
What has been filed or recorded for CRISPR Therapeutics (CRSP)?
The filings we hold for CRISPR Therapeutics, newest first: 8 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 9,578 shares | 483K USD notional · 0.010% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 36,884 shares | 2.0M USD notional · 0.038% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 300 shares | 17K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 102 shares | 6K USD notional · <0.001% of shares out |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 834 shares | 45K USD notional · 0.001% of shares out |
| 22 Sep 2026 | Fails to deliver | Shares failed to deliver | 6,400 shares | 373K USD notional · 0.007% of shares out |
| 21 Sep 2026 | Fails to deliver | Shares failed to deliver | 500 shares | 28K USD notional · 0.001% of shares out |
| 18 Sep 2026 | Fails to deliver | Shares failed to deliver | 142 shares | 8K USD notional · <0.001% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.94 USD | |
| 30 Jun 2026 | Financials | Total assets | 2.7B USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 1.7B USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.28 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −6.47 USD | |
| 31 Dec 2025 | Financials | Revenue | 3.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −581.6M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −6.47 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.17 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −2.40 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.58 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.34 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −1.01 USD |
What is Reddit saying about CRISPR Therapeutics (CRSP)?
Reddit mentioned CRSP 23 times in the 30 days to 1 November 2026, across 4 of the communities we track. All of them were scored for sentiment: 48% read bullish, 4% bearish and 48% neither. Reddit data updated 1 November 2026.
30-day window, Method
Mentions, 30 days 23Bullish 48%Bearish 4%Communities 4Against the market −6 points
How do Reddit mentions of CRISPR Therapeutics (CRSP) compare with its price?
Share ↗
Where CRISPR Therapeutics (CRSP) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 65% | 15 | +0.05 |
| r/stocks | 17% | 4 | +0.02 |
| r/etfs | 13% | 3 | +0.33 |
| r/investing | 4% | 1 | +0.05 |
Moves with CRISPR Therapeutics (CRSP)
Tickers whose daily Reddit volume rose and fell with CRISPR Therapeutics (CRSP)'s. Co-discussion, not price.
SPYI +0.57VGS +0.56CEASEFIRE +0.54VBR +0.53DOGE.X +0.52DHHF +0.50
How closely daily Reddit mention counts rose and fell together over the last 30 days (31 daily observations), Method
The threads carrying the mentions
30 days, shown as posted
| Thread | Community | Mentions | Latest |
|---|---|---|---|
| Is there a website where you can see the graph of a share before and after the stock split split?by u/gianoooos | r/stocks | 2 | 3 weeks ago |
Live discussion on Reddit, shown as posted. Titles link to the original threads.
CRISPR Therapeutics (CRSP): frequently asked questions
What did CRISPR Therapeutics shares close at?
CRISPR Therapeutics closed at 51.40 USD on 30 Oct 2026, down 5.29% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is CRISPR Therapeutics’ market cap?
CRISPR Therapeutics is worth 5.0B USD by market value as of 30 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is CRISPR Therapeutics’ revenue?
CRISPR Therapeutics reported revenue of 3.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have CRISPR Therapeutics insiders bought or sold shares recently?
In the 90 days to 2 Nov 2026, CRISPR Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 3 Oct 2025, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own CRISPR Therapeutics?
9 of the 45 funds we track reported a CRISPR Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were ARK Investment Management, Two Sigma Investments and D. E. Shaw & Co. See Funds
Have members of Congress traded CRISPR Therapeutics?
Yes. 1 trade in CRISPR Therapeutics appears in the congressional disclosures we hold: a purchase by Thomas R. Suozzi (House, NY) dated 3 Jun 2021, filed 23 Sep 2021. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did CRISPR Therapeutics last report earnings?
CRISPR Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.94 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about CRISPR Therapeutics?
CRISPR Therapeutics was mentioned 3 times in the last 7 days across the finance subreddits we track, and 23 times over the trailing 30 days. Of the 23 mentions scored for sentiment, 48% read bullish and 4% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings